Naya Biosciences, INC 8-K filings

INVO Fertility reports a 4% revenue increase in Q1 2025 while strategically divesting its majority stake in NAYA Therapeutics to concentrate on expanding its fertility services.

INVO Fertility incentivizes warrant exercise by issuing new warrants and reducing the exercise price of existing warrants.

INVO Fertility, Inc. entered into an agreement with an institutional investor to exercise existing warrants for $750,000 in gross proceeds, issuing new warrants in return.

INVO Fertility announces strong 2024 financial results with significant revenue growth and improved Adjusted EBITDA, while also detailing a strategic shift to focus on its core fertility operations.

INVO Fertility, Inc., formerly NAYA Biosciences, received a Nasdaq notice for failing to file its annual report on time but plans to regain compliance, while also changing its name and ticker symbol.

NAYA Biosciences held its 2024 annual meeting on April 9, 2025, where shareholders elected directors and ratified the appointment of M&K CPAs PLLC as the company's independent public accountant.

NAYA Biosciences has regained compliance with Nasdaq listing rules after implementing a reverse stock split and evidencing a minimum closing bid price.

NAYA Biosciences implemented a 1-for-12 reverse stock split on March 18, 2025, to comply with Nasdaq's minimum bid price requirement.

NAYA Biosciences postpones its annual stockholder meeting to April 9, 2025, to allow for resubmission of proposals and ensure compliance with Nasdaq listing rules.

NAYA Biosciences has successfully priced a public offering of 13,615,171 units, raising approximately $9.5 million to fund key strategic initiatives.

NAYA Biosciences has released an updated corporate investor presentation on its website, as announced in a recent SEC filing.

NAYA Biosciences finalized its merger with NAYA Therapeutics, resulting in a new combined entity and significant changes to its capital structure.

NAYA Biosciences has received notification from Nasdaq confirming its compliance with the Equity Rule, allowing it to continue listing on the Nasdaq Capital Market.

INVO Bioscience and NAYA Biosciences have finalized their merger, creating a combined company named NAYA Biosciences, which will focus on expanding its portfolio in fertility, oncology, and autoimmune disease treatments.

INVO Bioscience has entered into a merchant cash advance agreement, securing $251,750 in net proceeds to be used for working capital and general corporate purposes.

INVO Bioscience received a delisting notice from Nasdaq for failing to maintain a minimum share price and will restate past financial statements due to an accounting error.

INVO Bioscience and NAYA Biosciences have agreed to a fourth amendment of their merger agreement, extending the deadline to October 14, 2024, and modifying the terms of the deal.

INVO Bioscience announced a 481% year-over-year revenue increase and a $1.1 million improvement in adjusted EBITDA for the second quarter of 2024.

INVO Bioscience has extended the maturity date of its convertible notes to December 31, 2024, while also reducing the conversion and warrant exercise prices to $1.20.

INVO Bioscience has been granted an extension by Nasdaq to regain compliance with listing rules, while a subsidiary transferred ownership of a medical practice.

INVO Bioscience announced a 353% increase in revenue for the first quarter of 2024, alongside a significant improvement in adjusted EBITDA.

INVO Bioscience and NAYA Biosciences have amended their merger agreement, extending the deadline to June 30, 2024, and modifying the terms of an interim financing plan.

INVO Bioscience received a delisting notice from Nasdaq after failing to maintain the required minimum stockholders' equity, while also assigning a lease for a Tampa clinic for $475,000.

INVO Bioscience has amended its warrant agreement to allow for a reduction in the exercise price of its warrants, subsequently lowering it from $2.85 to $1.20 per share.

INVO Bioscience announced a significant increase in revenue for both the fourth quarter and full year 2023, driven by its expanding fertility clinic operations and the INVOcell technology.

INVO Bioscience has entered into a securities purchase agreement, securing a $275,000 promissory note along with warrants and shares, aimed at bolstering working capital.

INVO Bioscience has entered into an agreement with Triton Funds LP to sell up to 1,000,000 shares of common stock for gross proceeds of up to $850,000.

INVO Bioscience has entered into an agreement with Triton Funds LP for the sale of up to 1,000,000 shares of common stock and warrants, potentially raising $850,000.

INVO Bioscience has entered into an agreement to sell future sales, receiving $225,000 in net proceeds for working capital and general corporate purposes.

INVO Bioscience is seeking alternative funding after NAYA Bioscience failed to deliver a $500,000 payment for preferred stock by the agreed deadline.